Lethal myocardial reperfusion injury: a necessary evil?
- PMID: 21093938
- DOI: 10.1016/j.ijcard.2010.10.056
Lethal myocardial reperfusion injury: a necessary evil?
Abstract
Despite being the most effective means of limiting infarct size, coronary reperfusion comes at a price and induces additional damage to the myocardium. Lethal reperfusion injury (death of myocytes that were viable at the time of reperfusion) is an increasingly acknowledged phenomenon. There are many interconnected mechanisms involved in this type of cell death. Calcium overload (generating myocyte hypercontracture), rapid recovery of physiological pH, neutrophil infiltration of the ischemic area, opening of the mitochondrial permeability-transition-pore (PTP), and apoptotic cell death are among the more important mechanisms involved in reperfusion injury. The activation of a group of proteins called reperfusion injury salvage kinases (RISK) pathway confers protection against reperfusion injury, mainly by inhibiting the opening of the mitochondrial PTP. Many interventions have been tested in human trials triggered by encouraging animal studies. In the present review we will explain in detail the main mechanism involved in reperfusion injury, as well as the various approaches (pre-clinical and human trials) performed targeting these mechanisms. Currently, no intervention has been consistently shown to reduce reperfusion injury in large randomized multicenter trials, but the research in this field is intense and the future is highly promising.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Orphan targets for reperfusion injury.Cardiovasc Res. 2009 Jul 15;83(2):169-78. doi: 10.1093/cvr/cvp109. Epub 2009 Apr 7. Cardiovasc Res. 2009. PMID: 19351740 Review.
-
Unresolved issues in myocardial reperfusion injury.Cardiovasc Pathol. 2010 Jan-Feb;19(1):29-35. doi: 10.1016/j.carpath.2008.10.001. Epub 2008 Nov 20. Cardiovasc Pathol. 2010. PMID: 19026571 Review.
-
Postconditioning: from the bench to bedside.J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):117-30. doi: 10.1177/1074248410383174. Epub 2010 Oct 11. J Cardiovasc Pharmacol Ther. 2011. PMID: 20938041 Review.
-
Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury.Cardiovasc Res. 2004 Feb 15;61(3):481-97. doi: 10.1016/j.cardiores.2003.10.011. Cardiovasc Res. 2004. PMID: 14962479 Review.
-
The reduction of infarct size--forty years of research.Rev Port Cardiol. 2010 Jun;29(6):1037-53. Rev Port Cardiol. 2010. PMID: 20964114 Review. English, Portuguese.
Cited by
-
Inhibiting miR-155 protects against myocardial ischemia/reperfusion injury via targeted regulation of HIF-1α in rats.Iran J Basic Med Sci. 2019 Sep;22(9):1050-1058. doi: 10.22038/ijbms.2019.34853.8270. Iran J Basic Med Sci. 2019. PMID: 31807249 Free PMC article.
-
Macrophage Polarization in Myocardial Ischemia‒Reperfusion Injury: Pathophysiology and Therapeutic Targets.Drug Des Devel Ther. 2025 Jul 31;19:6519-6541. doi: 10.2147/DDDT.S516001. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40766819 Free PMC article. Review.
-
CTRP12 alleviates cardiomyocyte ischemia‑reperfusion injury via regulation of KLF15.Mol Med Rep. 2022 Jul;26(1):247. doi: 10.3892/mmr.2022.12763. Epub 2022 Jun 3. Mol Med Rep. 2022. PMID: 35656890 Free PMC article.
-
Oxidative Post-translational Protein Modifications upon Ischemia/Reperfusion Injury.Antioxidants (Basel). 2024 Jan 16;13(1):106. doi: 10.3390/antiox13010106. Antioxidants (Basel). 2024. PMID: 38247530 Free PMC article.
-
The low expression of miR-155 promotes the expression of SHP2 by inhibiting the activation of the ERK1/2 pathway and improves cell pyroptosis induced by I/R in mice.Aging (Albany NY). 2024 Mar 6;16(5):4778-4788. doi: 10.18632/aging.205631. Epub 2024 Mar 6. Aging (Albany NY). 2024. PMID: 38451182 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical